BRPI0513379A - derivados de sulfonamida - Google Patents

derivados de sulfonamida

Info

Publication number
BRPI0513379A
BRPI0513379A BRPI0513379-3A BRPI0513379A BRPI0513379A BR PI0513379 A BRPI0513379 A BR PI0513379A BR PI0513379 A BRPI0513379 A BR PI0513379A BR PI0513379 A BRPI0513379 A BR PI0513379A
Authority
BR
Brazil
Prior art keywords
sulfonamide derivatives
racemates
alzheimer
disease
compounds
Prior art date
Application number
BRPI0513379-3A
Other languages
English (en)
Inventor
Guido Galley
Roland Jakob-Roetne
Eric Argirios Kitas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0513379A publication Critical patent/BRPI0513379A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

DERIVADOS DE SULFONAMIDA. A invenção refere-se a Compostos da fórmula geral (I), em que R¬ 1¬-R¬ 5¬ e R¬ 2¬-R¬ 4¬ são como descrito nas reivindicações e a sais de adição de ácido farmaceuticamente adequados, enantiómeros puros óticos, racematos ou misturas diastereoméricas destes para o tratamento de doença de Alzheimer ou cânceres comuns.
BRPI0513379-3A 2004-07-13 2005-07-06 derivados de sulfonamida BRPI0513379A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103339 2004-07-13
PCT/EP2005/007268 WO2006005486A1 (en) 2004-07-13 2005-07-06 Sulfonamide derivatives

Publications (1)

Publication Number Publication Date
BRPI0513379A true BRPI0513379A (pt) 2008-05-06

Family

ID=34971295

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513379-3A BRPI0513379A (pt) 2004-07-13 2005-07-06 derivados de sulfonamida

Country Status (11)

Country Link
US (1) US7253158B2 (pt)
EP (1) EP1768960A1 (pt)
JP (1) JP4845883B2 (pt)
KR (1) KR100880972B1 (pt)
CN (2) CN101035765B (pt)
AU (1) AU2005261932B2 (pt)
BR (1) BRPI0513379A (pt)
CA (1) CA2573372A1 (pt)
MX (1) MX2007000468A (pt)
RU (1) RU2378258C2 (pt)
WO (1) WO2006005486A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325205T3 (es) 2001-12-20 2009-08-28 Bristol-Myers Squibb Company Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides.
US7569562B2 (en) 2005-01-18 2009-08-04 Elan Pharmaceuticals, Inc. N-substituted heterocyclic sulfonamides
EP1915345B1 (en) * 2005-08-12 2010-12-22 F. Hoffmann-La Roche AG Fluoro substituted 2-oxo azepan derivatives
CA2705489A1 (en) * 2007-12-05 2009-06-11 Basf Se Pyridylmethyl-sulfonamide compounds
US8457989B2 (en) * 2009-01-09 2013-06-04 Cerner Innovation, Inc. Direct reporting of adverse events
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
GB201009603D0 (en) * 2010-06-08 2010-07-21 Cambridge Entpr Ltd Anti-inflammatory agent
WO2012014127A1 (en) * 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CN102718711A (zh) * 2011-03-30 2012-10-10 北京德众万全医药科技有限公司 一种制备(R)-α-氨基己内酰胺盐酸盐的新方法
CN102911118B (zh) * 2012-11-09 2014-04-09 天津商业大学 一类苯并氮杂卓类衍生物及其制备方法和用途
CN103073498A (zh) * 2012-12-21 2013-05-01 北京万全德众医药生物技术有限公司 (R)-α-氨基己内酰胺的制备新方法
US20150141433A1 (en) * 2013-09-26 2015-05-21 Mnemosyne Pharmaceuticals, Inc. N-arylmethyl sulfonamide negative modulators of nr2a
ES2821010T3 (es) 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
US10500205B2 (en) 2015-12-09 2019-12-10 Cadent Therapeutics, Inc. Thienopyrimidinone NMDA receptor modulators and uses thereof
CN110337291A (zh) 2016-12-16 2019-10-15 帕珀莱恩医疗公司 治疗耳蜗突触病变的方法
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
CA3108519A1 (en) 2018-08-03 2020-04-30 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
CN109320456A (zh) * 2018-11-16 2019-02-12 天津商业大学 新晶型的抗肿瘤化合物及其制备方法和含其的组合物
CN118994009A (zh) * 2023-05-19 2024-11-22 中国石油化工股份有限公司 单苯甲基氨基己内酰胺的制备方法及其应用、功能性尼龙-6
CN117447298A (zh) * 2023-08-29 2024-01-26 上海泰坦科技股份有限公司 一种卤代甲基二氟甲基苯的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593888A (en) * 1977-12-22 1981-07-22 Wyeth John & Brother Ltd Hexahydroazepine piperidine and pyrrolidine derivatives
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
EP1268434A1 (en) * 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
EP1636196A1 (en) * 2003-03-14 2006-03-22 AstraZeneca AB Novel lactams and uses thereof
CA2544350A1 (en) * 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides

Also Published As

Publication number Publication date
RU2007100229A (ru) 2008-08-20
CN101747324A (zh) 2010-06-23
JP2008505948A (ja) 2008-02-28
US7253158B2 (en) 2007-08-07
AU2005261932B2 (en) 2011-10-13
WO2006005486A1 (en) 2006-01-19
US20060014945A1 (en) 2006-01-19
CN101035765B (zh) 2010-10-13
CN101035765A (zh) 2007-09-12
EP1768960A1 (en) 2007-04-04
KR100880972B1 (ko) 2009-02-03
MX2007000468A (es) 2007-03-08
RU2378258C2 (ru) 2010-01-10
KR20070026799A (ko) 2007-03-08
CA2573372A1 (en) 2006-01-19
JP4845883B2 (ja) 2011-12-28
AU2005261932A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
BR0214386A (pt) Método para identificação de enzimas de objetivação a tumor
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0519243A2 (pt) mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
EA200901373A1 (ru) Аминогетероциклические соединения
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
BR0210384A (pt) Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
NO20075111L (no) Farmasoytisk sammensetning
EA200401114A3 (ru) Замещённые гидроксиэтиламины
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
SE0401970D0 (sv) Novel compounds
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
BRPI0511874A (pt) derivados da pirrolopiridina
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.